Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin liposomal - ALZA

Next Previous
Drug Profile

Doxorubicin liposomal - ALZA

Alternative Names: Caelyx; Dox-SL; Doxil; JNS-002; Liposomal doxorubicin - ALZA; Pegylated liposomal doxorubicin; SPI 49

Latest Information Update: 18 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALZA Corporation
  • Developer Janssen Biotech; University of Kansas Medical Center; Xian-Janssen
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
  • Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Kaposi's sarcoma; Multiple myeloma; Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Kaposi's sarcoma; Multiple myeloma; Ovarian cancer

Most Recent Events

  • 14 Sep 2020 No development reported - Phase-II for Multiple myeloma (Combination therapy, First-line therapy, In the elderly, Newly diagnosed, In adults) in USA (IV)
  • 01 Sep 2016 Schering-Plough in collaboration with SOLTI Breast Cancer Research Group completes a phase II trial for Breast cancer in Spain (NCT00563953)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Japan (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top